Supplementary Figure S8 from MAPK Pathway–Activating Alteration and Immunotherapy Efficacy in Squamous Cell Lung Carcinoma: Results from the Randomized, Prospective SQUINT Trial

Authors:
Open Access
Publisher website
Google Scholar
Abstract
Supplementary Figure 8. Percentage (A) and number (B) of patients with mutations in genes belonging to MAPK1/3 signaling pathway and (C) an overview of MAPK1/3 pathway mutations and copy number variation.